TF ADC Competition Accelerates: Zai Ding Files for Cervical Cancer Approval, Xin Nuo Wei Launches Phase III for Pancreatic Cancer
Click the blue text Follow us This Issue Highlights Currently, the only approved TF-ADC drug globally is Seagen’s TIVDAK (tisotumab vedotin-tftv, for cervical cancer), with a carrier of VA–MMAE. It has been approved for sale in Japan. The domestic sales are handled by Zai Ding Pharmaceutical, which has submitted a listing application. Xin Nuo Wei’s … Read more